Pancreatic Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020

Pancreatic Cancer Diagnostic Tests include assays of mostly antibodies released in response to a pancreatic cancer and cancer-causing proteins. GlobalData’s Medical Devices sector report, “Pancreatic Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020″ provides comprehensive information about the Pancreatic Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Pancreatic Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to:

Extensive coverage of the Pancreatic Cancer Diagnostic Tests under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Pancreatic Cancer Diagnostic Tests pipeline products.

Review of Recent Developments in the segment / industry

The Pancreatic Cancer Diagnostic Tests Pipeline Assessment report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Glaucoma Drainage Device sunder development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

The major companies covered in the “Pancreatic Cancer Diagnostic Tests- Medical Devices Pipeline Assessment, 2020” report:

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025

• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports

• 64,000+ medical equipment company profiles

• 5,600+ company profiles of medical equipment manufacturers in China and India

• 2,200+ company profiles of medical equipment manufacturers in Japan

• 1,200+ companies’ revenue splits and market shares

• 1,600+ quarterly and annual medical equipment company financials

• 850+ medical equipment company SWOTs

• 28,000+ pipeline product profiles

• 56,400+ marketed product profiles

• 47,000+ clinical trials

• 41,500+ trial investigators

• 7,000+ reports on companies with products in development

• 44,000+ deals in the medical equipment industry

• 1,100+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

• 431,000+ Themes Content Items

• 600+ Influencers

• 1,900+ Analysts & Researchers

• 0.5m+ Community Members

• 141,000+ Macroeconomic Indicators

• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

Extensive coverage of the Pancreatic Cancer Diagnostic Tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Pancreatic Cancer Diagnostic Tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to:

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Pancreatic Cancer Diagnostic Tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product’s current stage of development, territory and estimated launch date

Companies mentioned

2cureX AB

3rd Street Diagnostics

A&G Pharmaceutical Inc

Abcodia Ltd

Acobiom

Advanced Marker Discovery SL

Alaunus Biosciences Inc

Amplified Sciences LLC

Anixa Diagnostics Corporation

Applied Proteomics Inc

Avant Diagnostics Inc

Axim Biotechnologies Inc

Berg LLC

BioMarker Strategies LLC

BiomaRx Inc

Bioprognos SL

Biouniversa srl

Cancer Research Technology Ltd

Captis Biotechnology Inc

Caris Life Sciences Inc

Cepheid Inc

Clovis Oncology Inc

Courtagen Life Sciences Inc

CS-Keys, Inc. (Inactive)

Di.V.A.L Toscana srl

Exact Sciences Corp

Fred Hutchinson Cancer Research Center

Fujirebio Diagnostics Inc

GlycoZym USA Inc

Health Discovery Corp

Houston Methodist Hospital

ImmunoCellular Therapeutics Ltd

Immunomedics Inc

Immunovia AB

Johns Hopkins University

JW Bioscience

Leitat Technological Center

Matrix-Bio Inc

MDNA Life Sciences Inc

Memorial Sloan Kettering Cancer Center

Merrimack Pharmaceuticals Inc

Metanomics Health GmbH

Milagen Inc

Myriad Genetics Inc

NanoScale Corp

Nanoview Biosciences Inc

NatiMab Therapeutics Srl

National Cheng-Kung University Hospital

Oncimmune (USA) LLC

Oncomatryx Biopharma SL

Onconome, Inc. (Inactive)

OPKO Health Inc

OTraces Inc

Oxford Gene Technology Ltd

Penn Medicine

Peri Rx Inc

Precision Biologics Inc

Preora Healthcare Inc

Proplex Technologies Llc

Protagen AG

Proteome Sciences Plc

Quanterix Corp

Reccan Diagnostics AB

RISE Life Science Corp

Rutgers The State University of New Jersey

Sanguine Diagnostics and Therapeutics Inc

SDIX LLC

Shenzhen Mindray Bio-Medical Electronics Co Ltd

Sienna Cancer Diagnostics Ltd

SomaLogic Inc

Stanford University

Taizhou ZECEN Biotech Co Ltd

Temple University Health System

Thomas Jefferson University

University of California San Francisco

University of Illinois at Chicago

University of Liverpool

University of Pennsylvania

University of Texas MD Anderson Cancer Center

University of Washington

US Biomarkers Inc

Vajra Instruments Inc

Vastcon Inc

Ventana Medical Systems Inc

Viomics Inc.

VolitionRX Ltd

ZORA Biosciences Oy

Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 13

2 Introduction 14

2.1 Pancreatic Cancer Overview 14

3 Products under Development 15

3.1 Pancreatic Cancer – Pipeline Products by Stage of Development 15

3.2 Pancreatic Cancer – Pipeline Products by Territory 16

3.3 Pancreatic Cancer – Pipeline Products by Regulatory Path 17

3.4 Pancreatic Cancer – Pipeline Products by Estimated Approval Date 18

3.5 Pancreatic Cancer – Ongoing Clinical Trials 19

4 Pancreatic Cancer – Pipeline Products under Development by Companies 20

4.1 Pancreatic Cancer Companies – Pipeline Products by Stage of Development 20

4.2 Pancreatic Cancer – Pipeline Products by Stage of Development 24

5 Pancreatic Cancer Companies and Product Overview 28

5.1 2cureX AB Company Overview 28

5.1.1 2cureX AB Pipeline Products & Ongoing Clinical Trials Overview 28

5.2 3rd Street Diagnostics Company Overview 31

5.2.1 3rd Street Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 31

5.3 A&G Pharmaceutical Inc Company Overview 32

5.3.1 A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.4 Abcodia Ltd Company Overview 33

5.4.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

5.5 Acobiom Company Overview 34

5.5.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview 34

5.6 Advanced Marker Discovery SL Company Overview 39

5.6.1 Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 39

5.7 Alaunus Biosciences Inc Company Overview 40

5.7.1 Alaunus Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 40

5.8 Amplified Sciences LLC Company Overview 41

5.8.1 Amplified Sciences LLC Pipeline Products & Ongoing Clinical Trials Overview 41

5.9 Anixa Diagnostics Corporation Company Overview 42

5.9.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 42

5.10 Applied Proteomics Inc Company Overview 47

5.10.1 Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 47

5.11 Avant Diagnostics Inc Company Overview 48

5.11.1 Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 48

5.12 Axim Biotechnologies Inc Company Overview 49

5.12.1 Axim Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview 49

5.13 Berg LLC Company Overview 50

5.13.1 Berg LLC Pipeline Products & Ongoing Clinical Trials Overview 50

5.14 BioMarker Strategies LLC Company Overview 51

5.14.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 51

5.15 BiomaRx Inc Company Overview 52

5.15.1 BiomaRx Inc Pipeline Products & Ongoing Clinical Trials Overview 52

5.16 Bioprognos SL Company Overview 55

5.16.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 55

5.17 Biouniversa srl Company Overview 56

5.17.1 Biouniversa srl Pipeline Products & Ongoing Clinical Trials Overview 56

5.18 Cancer Research Technology Ltd Company Overview 58

5.18.1 Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

5.19 Captis Biotechnology Inc Company Overview 59

5.19.1 Captis Biotechnology Inc Pipeline Products & Ongoing Clinical Trials Overview 59

5.20 Caris Life Sciences Inc Company Overview 60

5.20.1 Caris Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.21 Cepheid Inc Company Overview 61

5.21.1 Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview 61

5.22 Clovis Oncology Inc Company Overview 63

5.22.1 Clovis Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 63

5.23 Courtagen Life Sciences Inc Company Overview 64

5.23.1 Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 64

5.24 CS-Keys, Inc. (Inactive) Company Overview 65

5.24.1 CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 65

5.25 Di.V.A.L Toscana srl Company Overview 66

5.25.1 Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 66

5.26 Exact Sciences Corp Company Overview 67

5.26.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 67

5.27 Fred Hutchinson Cancer Research Center Company Overview 68

5.27.1 Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 68

5.28 Fujirebio Diagnostics Inc Company Overview 69

5.28.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 69

5.29 GlycoZym USA Inc Company Overview 70

5.29.1 GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 70

5.30 Health Discovery Corp Company Overview 71

5.30.1 Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 71

5.31 Houston Methodist Hospital Company Overview 72

5.31.1 Houston Methodist Hospital Pipeline Products & Ongoing Clinical Trials Overview 72

5.32 ImmunoCellular Therapeutics Ltd Company Overview 73

5.32.1 ImmunoCellular Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 73

5.33 Immunomedics Inc Company Overview 74

5.33.1 Immunomedics Inc Pipeline Products & Ongoing Clinical Trials Overview 74

5.34 Immunovia AB Company Overview 75

5.34.1 Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 75

5.35 Johns Hopkins University Company Overview 76

5.35.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 76

5.36 JW Bioscience Company Overview 77

5.36.1 JW Bioscience Pipeline Products & Ongoing Clinical Trials Overview 77

5.37 Leitat Technological Center Company Overview 78

5.37.1 Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 78

5.38 Matrix-Bio Inc Company Overview 80

5.38.1 Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 80

5.39 MDNA Life Sciences Inc Company Overview 81

5.39.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 81

5.40 Memorial Sloan Kettering Cancer Center Company Overview 82

5.40.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 82

5.41 Merrimack Pharmaceuticals Inc Company Overview 83

5.41.1 Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 83

5.42 Metanomics Health GmbH Company Overview 84

5.42.1 Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 84

5.43 Milagen Inc Company Overview 85

5.43.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 85

5.44 Myriad Genetics Inc Company Overview 86

5.44.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 86

5.45 NanoScale Corp Company Overview 87

5.45.1 NanoScale Corp Pipeline Products & Ongoing Clinical Trials Overview 87

5.46 Nanoview Biosciences Inc Company Overview 88

5.46.1 Nanoview Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 88

5.47 NatiMab Therapeutics Srl Company Overview 89

5.47.1 NatiMab Therapeutics Srl Pipeline Products & Ongoing Clinical Trials Overview 89

5.48 National Cheng-Kung University Hospital Company Overview 92

5.48.1 National Cheng-Kung University Hospital Pipeline Products & Ongoing Clinical Trials Overview 92

5.49 Oncimmune (USA) LLC Company Overview 93

5.49.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 93

5.50 Oncomatryx Biopharma SL Company Overview 94

5.50.1 Oncomatryx Biopharma SL Pipeline Products & Ongoing Clinical Trials Overview 94

5.51 Onconome, Inc. (Inactive) Company Overview 96

5.51.1 Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 96

5.52 OPKO Health Inc Company Overview 98

5.52.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.53 OTraces Inc Company Overview 99

5.53.1 OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 99

5.54 Oxford Gene Technology Ltd Company Overview 100

5.54.1 Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 100

5.55 Penn Medicine Company Overview 101

5.55.1 Penn Medicine Pipeline Products & Ongoing Clinical Trials Overview 101

5.56 Peri Rx Inc Company Overview 102

5.56.1 Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 102

5.57 Precision Biologics Inc Company Overview 103

5.57.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 103

5.58 Preora Healthcare Inc Company Overview 105

5.58.1 Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 105

5.59 Proplex Technologies Llc Company Overview 106

5.59.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 106

5.60 Protagen AG Company Overview 107

5.60.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 107

5.61 Proteome Sciences Plc Company Overview 108

5.61.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 108

5.62 Quanterix Corp Company Overview 110

5.62.1 Quanterix Corp Pipeline Products & Ongoing Clinical Trials Overview 110

5.63 Reccan Diagnostics AB Company Overview 111

5.63.1 Reccan Diagnostics AB Pipeline Products & Ongoing Clinical Trials Overview 111

5.64 RISE Life Science Corp Company Overview 113

5.64.1 RISE Life Science Corp Pipeline Products & Ongoing Clinical Trials Overview 113

5.65 Rutgers The State University of New Jersey Company Overview 114

5.65.1 Rutgers The State University of New Jersey Pipeline Products & Ongoing Clinical Trials Overview 114

5.66 Sanguine Diagnostics and Therapeutics Inc Company Overview 115

5.66.1 Sanguine Diagnostics and Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 115

5.67 SDIX LLC Company Overview 117

5.67.1 SDIX LLC Pipeline Products & Ongoing Clinical Trials Overview 117

5.68 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 118

5.68.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 118

5.69 Sienna Cancer Diagnostics Ltd Company Overview 120

5.69.1 Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 120

5.70 SomaLogic Inc Company Overview 122

5.70.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 122

5.71 Stanford University Company Overview 123

5.71.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 123

5.72 Taizhou ZECEN Biotech Co Ltd Company Overview 124

5.72.1 Taizhou ZECEN Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 124

5.73 Temple University Health System Company Overview 125

5.73.1 Temple University Health System Pipeline Products & Ongoing Clinical Trials Overview 125

5.74 Thomas Jefferson University Company Overview 126

5.74.1 Thomas Jefferson University Pipeline Products & Ongoing Clinical Trials Overview 126

5.75 University of California San Francisco Company Overview 127

5.75.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 127

5.76 University of Illinois at Chicago Company Overview 128

5.76.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 128

5.77 University of Liverpool Company Overview 129

5.77.1 University of Liverpool Pipeline Products & Ongoing Clinical Trials Overview 129

5.78 University of Pennsylvania Company Overview 133

5.78.1 University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 133

5.79 University of Texas MD Anderson Cancer Center Company Overview 135

5.79.1 University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 135

5.80 University of Washington Company Overview 137

5.80.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 137

5.81 US Biomarkers Inc Company Overview 138

5.81.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 138

5.82 Vajra Instruments Inc Company Overview 139

5.82.1 Vajra Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 139

5.83 Vastcon Inc Company Overview 140

5.83.1 Vastcon Inc Pipeline Products & Ongoing Clinical Trials Overview 140

5.84 Ventana Medical Systems Inc Company Overview 141

5.84.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 141

5.85 Viomics Inc. Company Overview 142

5.85.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 142

5.86 VolitionRX Ltd Company Overview 143

5.86.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 143

5.87 ZORA Biosciences Oy Company Overview 146

5.87.1 ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 146

6 Pancreatic Cancer- Recent Developments 147

6.1 Aug 10, 2020: Tevogen Bio announces partnership with preeminent Scientist Professor Neal Flomenberg, M.D., to investigate proprietary T-Cell therapy for treatment of COVID-19 & influenza 147

6.2 Jul 30, 2020: Moderna announces resignation of Dr. Elizabeth Nabel from Board of Directors 147

6.3 Jul 15, 2020: Artificial intelligence shows potential in identifying those at risk of pancreatic cancer 148

6.4 Jul 02, 2020: Artificial intelligence brings pancreatic cancer screening one step closer to reality 148

6.5 Jun 26, 2020: Sienna Cancer Diagnostics: Change of registered office 150

6.6 May 13, 2020: OPKO Health’s BioReference Laboratories and Westchester Medical Center Health Network enter into strategic laboratory collaboration to deliver operational and diagnostic services 150

6.7 Apr 30, 2020: Focused Ultrasound Foundation and Pancreatic Cancer UK Partner to Fund Innovative Study 150

6.8 Apr 22, 2020: Risk prediction model that combines clinical and genetic factors with circulating biomarkers could identify those at higher risk of pancreatic cancer 152

6.9 Apr 16, 2020: Blood test may help doctors catch pancreatic cancer early 153

6.10 Apr 15, 2020: Precision Biologics took $150,000-350,000 PPP government loan for COVID-19-struck small businesses, FOIA request shows 154

6.11 Apr 03, 2020: NeoGenomics integrates HALO from Indica Labs 154

6.12 Mar 06, 2020: 2cureX is accelerating the commercialization of IndiTreat by signing two distributor agreements to prepare for launch in second half of 2020 155

6.13 Feb 27, 2020: Immunomedics reports fourth quarter and full year 2019 results and provides corporate update 156

6.14 Feb 27, 2020: Immunomedics appoints Robert W. Azelby to board of directors 158

6.15 Feb 26, 2020: Mayo Clinic reports ‘remarkable growth’ in 2019 158

6.16 Feb 24, 2020: Halozyme announces CFO transition 158

6.17 Feb 14, 2020: Immunovia full year report 2019 159

6.18 Feb 14, 2020: Immunomedics appoints Dr. Loretta Itri Chief Medical Officer 159

6.19 Feb 11, 2020: Exact Sciences announces fourth-quarter 2019 results 160

6.20 Feb 06, 2020: Myriad announces leadership transition 161

6.21 Feb 06, 2020: Myriad Genetics reports fiscal second-quarter 2020 financial results 162

6.22 Jan 30, 2020: The Crown Princess of Sweden and Prince Daniel visited Immunovia in Lund 163

6.23 Jan 30, 2020: OGT launches breakthrough NGS panel for constitutional cytogenetics 164

6.24 Jan 17, 2020: INTERPACE Biosciences: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers 165

6.25 Jan 14, 2020: Dr. Thomas P. Slavin named Senior Vice President of Medical Affairs for Myriad Oncology 166

6.26 Jan 13, 2020: Immunovia strengthen management with new senior VP of Sales North America ahead of the IMMray PanCan-d Test launch 166

6.27 Jan 12, 2020: Exact Sciences announces preliminary fourth quarter 2019 results 167

6.28 Jan 07, 2020: Clovis Oncology announces debt refinancing transaction 168

6.29 Jan 07, 2020: Clovis Oncology announces product revenues for the fourth quarter and full year 2019 168

6.30 Jan 06, 2020: Sienna makes Board appointment 169

6.31 Dec 23, 2019: Mayo Clinic names chief digital officer to lead transformative digital strategy, create Center for Digital Health 169

6.32 Dec 13, 2019: Hospitals and cancer care givers can now offer the IndiTreat test to their cancer patients. 170

6.33 Dec 13, 2019: 2cureX presented progression in the IndiTreat immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 170

6.34 Dec 03, 2019: Dr. John Halamka named president of Mayo Clinic Platform 171

7 Appendix 173

7.1 Methodology 173

7.2 About GlobalData 177

7.3 Contact Us 177

List of Tables

Table 1: Pancreatic Cancer – Pipeline Products by Stage of Development 15

Table 2: Pancreatic Cancer – Pipeline Products by Territory 16

Table 3: Pancreatic Cancer – Pipeline Products by Regulatory Path 17

Table 4: Pancreatic Cancer – Pipeline Products by Estimated Approval Date 18

Table 5: Pancreatic Cancer – Ongoing Clinical Trials 19

Table 6: Pancreatic Cancer Companies – Pipeline Products by Stage of Development 20

Table 7: Pancreatic Cancer – Pipeline Products by Stage of Development 24

Table 8: 2cureX AB Pipeline Products & Ongoing Clinical Trials Overview 28

Table 9: IndiTreat – PC – Product Status 28

Table 10: IndiTreat – PC – Product Description 28

Table 11: 2cureX AB – Ongoing Clinical Trials Overview 29

Table 12: IndiTreat – PC – Predictive Value of In-vitro Anti-cancer Therapy Sensitivity Testing on Tumoroids from Patients with Metastatic Pancreatic Cancer 30

Table 13: 3rd Street Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 31

Table 14: Diagnostic Test Kit – Pancreatic Ductal Adenocarcinoma – Product Status 31

Table 15: Diagnostic Test Kit – Pancreatic Ductal Adenocarcinoma – Product Description 31

Table 16: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 17: Companion Diagnostic Test – Pancreatic Cancer – Product Status 32

Table 18: Companion Diagnostic Test – Pancreatic Cancer – Product Description 32

Table 19: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

Table 20: Diagnostic Assay – Pancreatic Cancer – Product Status 33

Table 21: Diagnostic Assay – Pancreatic Cancer – Product Description 33

Table 22: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 34

Table 23: Companion Diagnostic Assay – Masitinib – Product Status 34

Table 24: Companion Diagnostic Assay – Masitinib – Product Description 34

Table 25: Diagnostic/Prognostic Assay – Pancreatic Cancer – Product Status 35

Table 26: Diagnostic/Prognostic Assay – Pancreatic Cancer – Product Description 35

Table 27: GemciTest – Product Status 35

Table 28: GemciTest – Product Description 36

Table 29: Acobiom – Ongoing Clinical Trials Overview 37

Table 30: GemciTest – Evaluation of GEMCITEST in Patients with Pancreatic Cancer and Treated by Chemotherapy (GEMCIPANC) 38

Table 31: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 39

Table 32: PancreaDix – Product Status 39

Table 33: PancreaDix – Product Description 39

Table 34: Alaunus Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 40

Table 35: Diagnostic Assay – Pancreatic Cancer – Product Status 40

Table 36: Diagnostic Assay – Pancreatic Cancer – Product Description 40

Table 37: Amplified Sciences LLC Pipeline Products & Ongoing Clinical Trials Overview 41

Table 38: PanCystPro – Product Status 41

Table 39: PanCystPro – Product Description 41

Table 40: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 42

Table 41: Cchek – Pancreatic Cancer Confirmatory Test – Product Status 42

Table 42: Cchek – Pancreatic Cancer Confirmatory Test – Product Description 42

Table 43: Cchek – Pancreatic Cancer Recurrence Test – Product Status 43

Table 44: Cchek – Pancreatic Cancer Recurrence Test – Product Description 43

Table 45: Cchek – Pancreatic Cancer Screening Test – Product Status 43

Table 46: Cchek – Pancreatic Cancer Screening Test – Product Description 44

Table 47: Cchek – Pancreatic Cancer Treatment Monitoring Test – Product Status 44

Table 48: Cchek – Pancreatic Cancer Treatment Monitoring Test – Product Description 44

Table 49: Anixa Diagnostics Corporation – Ongoing Clinical Trials Overview 45

Table 50: Cchek – Pancreatic Cancer Screening Test – The Coupling of MDSCs with a Computational Analytic Method to Detect Solid Tumors 46

Table 51: Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 47

Table 52: API Diagnostic Test – Pancreatic Cancer – Product Status 47

Table 53: API Diagnostic Test – Pancreatic Cancer – Product Description 47

Table 54: Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 48

Table 55: TheraLink Assay – Pancreatic Cancer – Product Status 48

Table 56: TheraLink Assay – Pancreatic Cancer – Product Description 48

Table 57: Axim Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview 49

Table 58: Diagnostic Test – Pancreatic Cancer – Product Status 49

Table 59: Diagnostic Test – Pancreatic Cancer – Product Description 49

Table 60: Berg LLC Pipeline Products & Ongoing Clinical Trials Overview 50

Table 61: Biomarker Assay – Pancreatic Cancer – Product Status 50

Table 62: Biomarker Assay – Pancreatic Cancer – Product Description 50

Table 63: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 51

Table 64: Ex Vivo Biomarker Test – Pancreatic Cancer – Product Status 51

Table 65: Ex Vivo Biomarker Test – Pancreatic Cancer – Product Description 51

Table 66: BiomaRx Inc Pipeline Products & Ongoing Clinical Trials Overview 52

Table 67: Non-Invasive Diagnostic Test – Pancreatic Cancer – Product Status 52

Table 68: Non-Invasive Diagnostic Test – Pancreatic Cancer – Product Description 52

Table 69: PDAC Diagnostic v2.0 – Product Status 53

Table 70: PDAC Diagnostic v2.0 – Product Description 53

Table 71: PDAC FFPE Biopsy Test v1.0 – Product Status 53

Table 72: PDAC FFPE Biopsy Test v1.0 – Product Description 54

Table 73: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 55

Table 74: MBDAA Pancreatic Cancer Test – Product Status 55

Table 75: MBDAA Pancreatic Cancer Test – Product Description 55

Table 76: Biouniversa srl Pipeline Products & Ongoing Clinical Trials Overview 56

Table 77: BAG3 ELISA Kit – Pancreatic Adenocarcinoma – Product Status 56

Table 78: BAG3 ELISA Kit – Pancreatic Adenocarcinoma – Product Description 56

Table 79: BAG3 ELISA Kit – Pancreatic Adenocarcinoma Early Diagnosis – Product Status 57

Table 80: BAG3 ELISA Kit – Pancreatic Adenocarcinoma Early Diagnosis – Product Description 57

Table 81: Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

Table 82: IHC Based Test – Pancreatic Cancer – Product Status 58

Table 83: IHC Based Test – Pancreatic Cancer – Product Description 58

Table 84: Captis Biotechnology Inc Pipeline Products & Ongoing Clinical Trials Overview 59

Table 85: Diagnostic Test – Precancerous Pancreatic Lesions – Product Status 59

Table 86: Diagnostic Test – Precancerous Pancreatic Lesions – Product Description 59

Table 87: Caris Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 60

Table 88: Companion Diagnostic Assay – Pancreatic Cancer – Product Status 60

Table 89: Companion Diagnostic Assay – Pancreatic Cancer – Product Description 60

Table 90: Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview 61

Table 91: XPERT Pancreatic CA Early Detection Test – Product Status 61

Table 92: XPERT Pancreatic CA Early Detection Test – Product Description 61

Table 93: Xpert Pancreatic CA Monitor Assay – Product Status 62

Table 94: Xpert Pancreatic CA Monitor Assay – Product Description 62

Table 95: Clovis Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 63

Table 96: hENT1 Companion Diagnostic Test – Product Status 63

Table 97: hENT1 Companion Diagnostic Test – Product Description 63

Table 98: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 64

Table 99: Pancreatic Cancer Diagnostic Panel – Product Status 64

Table 100: Pancreatic Cancer Diagnostic Panel – Product Description 64

Table 101: CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 65

Table 102: caPCNA – Pancreatic Cancer – Product Status 65

Table 103: caPCNA – Pancreatic Cancer – Product Description 65

Table 104: Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 66

Table 105: NanoMabKv – Pancreatic Cancer – Product Status 66

Table 106: NanoMabKv – Pancreatic Cancer – Product Description 66

Table 107: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 67

Table 108: Liquid Biopsy Test – Pancreatic Cancer – Product Status 67

Table 109: Liquid Biopsy Test – Pancreatic Cancer – Product Description 67

Table 110: Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 68

Table 111: Diagnostic Test – Pancreatic Cancer – Product Status 68

Table 112: Diagnostic Test – Pancreatic Cancer – Product Description 68

Table 113: Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 69

Table 114: Lumipulse G – NCC-ST439 Assay – Product Status 69

Table 115: Lumipulse G – NCC-ST439 Assay – Product Description 69

Table 116: GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 70

Table 117: Diagnostic Assay – Pancreatic Cancer – Product Status 70

Table 118: Diagnostic Assay – Pancreatic Cancer – Product Description 70

Table 119: Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 71

Table 120: Diagnostic Test – Pancreatic Cancer – Product Status 71

Table 121: Diagnostic Test – Pancreatic Cancer – Product Description 71

Table 122: Houston Methodist Hospital Pipeline Products & Ongoing Clinical Trials Overview 72

Table 123: Diagnostic Test – Pancreatic Ductal Adenocarcinoma – Product Status 72

Table 124: Diagnostic Test – Pancreatic Ductal Adenocarcinoma – Product Description 72

Table 125: ImmunoCellular Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 73

Table 126: Diagnostic Test – Pancreatic Cancer – Product Status 73

Table 127: Diagnostic Test – Pancreatic Cancer – Product Description 73

Table 128: Immunomedics Inc Pipeline Products & Ongoing Clinical Trials Overview 74

Table 129: Companion Diagnostic Assay – Clivatuzumab – Product Status 74

Table 130: Companion Diagnostic Assay – Clivatuzumab – Product Description 74

Table 131: Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 75

Table 132: IMMray PanCan-m Test – Product Status 75

Table 133: IMMray PanCan-m Test – Product Description 75

Table 134: Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 76

Table 135: Magnetic Bead-Based Multiplex Immunoassay – Pancreatic Cancer – Product Status 76

Table 136: Magnetic Bead-Based Multiplex Immunoassay – Pancreatic Cancer – Product Description 76

Table 137: JW Bioscience Pipeline Products & Ongoing Clinical Trials Overview 77

Table 138: Diagnostic Kit – Pancreatic Cancer – Product Status 77

Table 139: Diagnostic Kit – Pancreatic Cancer – Product Description 77

Table 140: Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 78

Table 141: ELISA Kit – S100A4 – Pancreatic Cancer – Product Status 78

Table 142: ELISA Kit – S100A4 – Pancreatic Cancer – Product Description 78

Table 143: ELISA Kit – S100P – Pancreatic Cancer – Product Status 79

Table 144: ELISA Kit – S100P – Pancreatic Cancer – Product Description 79

Table 145: Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 80

Table 146: VeraMarker Pancreatic Cancer Test – Product Status 80

Table 147: VeraMarker Pancreatic Cancer Test – Product Description 80

Table 148: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 81

Table 149: Mitomic Pancreatic Test – Product Status 81

Table 150: Mitomic Pancreatic Test – Product Description 81

Table 151: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 82

Table 152: Diagnostic Test – Pancreatic Ductal Adenocarcinoma – Product Status 82

Table 153: Diagnostic Test – Pancreatic Ductal Adenocarcinoma – Product Description 82

Table 154: Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 83

Table 155: MM-141 Companion Diagnostic Assay – Pancreatic Cancer – Product Status 83

Table 156: MM-141 Companion Diagnostic Assay – Pancreatic Cancer – Product Description 83

Table 157: Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 84

Table 158: Diagnostic Assay – Pancreatic Cancer – Product Status 84

Table 159: Diagnostic Assay – Pancreatic Cancer – Product Description 84

Table 160: Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 85

Table 161: Immunoassay – Pancreatic Cancer – Product Status 85

Table 162: Immunoassay – Pancreatic Cancer – Product Description 85

Table 163: Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 86

Table 164: myPath Pancreatic Cancer – Product Status 86

Table 165: myPath Pancreatic Cancer – Product Description 86

Table 166: NanoScale Corp Pipeline Products & Ongoing Clinical Trials Overview 87

Table 167: Diagnostic Test – Pancreatic Cancer – Product Status 87

Table 168: Diagnostic Test – Pancreatic Cancer – Product Description 87

Table 169: Nanoview Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 88

Table 170: PDAC Assay – Product Status 88

Table 171: PDAC Assay – Product Description 88

Table 172: NatiMab Therapeutics Srl Pipeline Products & Ongoing Clinical Trials Overview 89

Table 173: ELISA-Based ENOA-Abs Kit – Product Status 89

Table 174: ELISA-Based ENOA-Abs Kit – Product Description 89

Table 175: ELISA-based EZR-Abs Kit – Product Status 90

Table 176: ELISA-based EZR-Abs Kit – Product Description 90

Table 177: Three Marker Panel Assay – Product Status 90

Table 178: Three Marker Panel Assay – Product Description 91

Table 179: National Cheng-Kung University Hospital Pipeline Products & Ongoing Clinical Trials Overview 92

Table 180: Diagnostic Biomarker – Pancreatic Cancer – Product Status 92

Table 181: Diagnostic Biomarker – Pancreatic Cancer – Product Description 92

Table 182: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 93

Table 183: EarlyCDT – Pancreatic Cancer – Product Status 93

Table 184: EarlyCDT – Pancreatic Cancer – Product Description 93

Table 185: Oncomatryx Biopharma SL Pipeline Products & Ongoing Clinical Trials Overview 94

Table 186: ELISA-Based Companion Diagnostic Kit – MTX3 – Product Status 94

Table 187: ELISA-Based Companion Diagnostic Kit – MTX3 – Product Description 94

Table 188: Immunohistochemistry Based Companion Diagnostic Kit – MTX3 – Product Status 95

Table 189: Immunohistochemistry Based Companion Diagnostic Kit – MTX3 – Product Description 95

Table 190: Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 96

Table 191: Pan Cancer Screening and Detection Test – Product Status 96

Table 192: Pan Cancer Screening and Detection Test – Product Description 96

Table 193: Pan-Cancer Metastatic Marker Test – Product Status 97

Table 194: Pan-Cancer Metastatic Marker Test – Product Description 97

Table 195: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 98

Table 196: Diagnostic Test – Pancreatic Cancer – Product Status 98

Table 197: Diagnostic Test – Pancreatic Cancer – Product Description 98

Table 198: OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 99

Table 199: Protein Based Diagnostic Test – Pancreatic Cancer – Product Status 99

Table 200: Protein Based Diagnostic Test – Pancreatic Cancer – Product Description 99

Table 201: Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 100

Table 202: Diagnostic Test – Pancreatic Cancer – Product Status 100

Table 203: Diagnostic Test – Pancreatic Cancer – Product Description 100

Table 204: Penn Medicine Pipeline Products & Ongoing Clinical Trials Overview 101

Table 205: Liquid Biopsy Test – Pancreatic Cancer – Product Status 101

Table 206: Liquid Biopsy Test – Pancreatic Cancer – Product Description 101

Table 207: Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 102

Table 208: Saliva Test – Pancreatic Cancer – Product Status 102

Table 209: Saliva Test – Pancreatic Cancer – Product Description 102

Table 210: Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 103

Table 211: Diagnostic Assay – Pancreatic Cancer – Product Status 103

Table 212: Diagnostic Assay – Pancreatic Cancer – Product Description 103

Table 213: NEO-301 IHC Test – Product Status 104

Table 214: NEO-301 IHC Test – Product Description 104

Table 215: Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 105

Table 216: Cancer Risk Stratification Test – Pancreatic Cancer – Product Status 105

Table 217: Cancer Risk Stratification Test – Pancreatic Cancer – Product Description 105

Table 218: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 106

Table 219: Biomarker Diagnostic Test – Pancreatic Cancer – Product Status 106

Table 220: Biomarker Diagnostic Test – Pancreatic Cancer – Product Description 106

Table 221: Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 107

Table 222: Diagnostic Assay – Pancreatic Cancer – Product Status 107

Table 223: Diagnostic Assay – Pancreatic Cancer – Product Description 107

Table 224: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 108

Table 225: SysQuant Global Phosphorylation Assay – Biopsy Tissue – Product Status 108

Table 226: SysQuant Global Phosphorylation Assay – Biopsy Tissue – Product Description 109

Table 227: Quanterix Corp Pipeline Products & Ongoing Clinical Trials Overview 110

Table 228: Simoa HD-1 Analyzer – Pancreatic Cancer – Product Status 110

Table 229: Simoa HD-1 Analyzer – Pancreatic Cancer – Product Description 110

Table 230: Reccan Diagnostics AB Pipeline Products & Ongoing Clinical Trials Overview 111

Table 231: Prognostic Test – Pancreatic Cancer – Product Status 111

Table 232: Prognostic Test – Pancreatic Cancer – Product Description 111

Table 233: Protein Based Assay – Pancreatic Cancer – Product Status 112

Table 234: Protein Based Assay – Pancreatic Cancer – Product Description 112

Table 235: RISE Life Science Corp Pipeline Products & Ongoing Clinical Trials Overview 113

Table 236: Diagnostic Test – Pancreatic Cancer – Product Status 113

Table 237: Diagnostic Test – Pancreatic Cancer – Product Description 113

Table 238: Rutgers The State University of New Jersey Pipeline Products & Ongoing Clinical Trials Overview 114

Table 239: Blood Test – Pancreatic Cancer – Product Status 114

Table 240: Blood Test – Pancreatic Cancer – Product Description 114

Table 241: Sanguine Diagnostics and Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 115

Table 242: Muc4/16 Assay – Pancreatic Cancer – Product Status 115

Table 243: Muc4/16 Assay – Pancreatic Cancer – Product Description 115

Table 244: Seromic Mucin Signature Biomarker Test – Pancreatic Cancer – Product Status 116

Table 245: Seromic Mucin Signature Biomarker Test – Pancreatic Cancer – Product Description 116

Table 246: SDIX LLC Pipeline Products & Ongoing Clinical Trials Overview 117

Table 247: Pancreatic Cancer Assay – Product Status 117

Table 248: Pancreatic Cancer Assay – Product Description 117

Table 249: Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 118

Table 250: CL-2000i – CA242 Test – Product Status 118

Table 251: CL-2000i – CA242 Test – Product Description 119

Table 252: Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 120

Table 253: Diagnostic Test – Pancreatic Cancer – Product Status 120

Table 254: Diagnostic Test – Pancreatic Cancer – Product Description 120

Table 255: Sienna Test – Pancreatic Cancer – Product Status 121

Table 256: Sienna Test – Pancreatic Cancer – Product Description 121

Table 257: SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 122

Table 258: SomaSignal Test – Pancreatic Cancer – Product Status 122

Table 259: SomaSignal Test – Pancreatic Cancer – Product Description 122

Table 260: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 123

Table 261: Biomarker Assay – Pancreatic Cyst – Product Status 123

Table 262: Biomarker Assay – Pancreatic Cyst – Product Description 123

Table 263: Taizhou ZECEN Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 124

Table 264: CA242 Detection Kit – Product Status 124

Table 265: CA242 Detection Kit – Product Description 124

Table 266: Temple University Health System Pipeline Products & Ongoing Clinical Trials Overview 125

Table 267: Diagnostic Test – Pancreatic Cancer – Product Status 125

Table 268: Diagnostic Test – Pancreatic Cancer – Product Description 125

Table 269: Thomas Jefferson University Pipeline Products & Ongoing Clinical Trials Overview 126

Table 270: Diagnostic Test – Pancreatic Cancer – Product Status 126

Table 271: Diagnostic Test – Pancreatic Cancer – Product Description 126

Table 272: University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 127

Table 273: Liquid Biopsy Diagnostic Test – Pancreatic Cancer – Product Status 127

Table 274: Liquid Biopsy Diagnostic Test – Pancreatic Cancer – Product Description 127

Table 275: University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 128

Table 276: Diagnostic Test – Pancreatic Cancer – Product Status 128

Table 277: Diagnostic Test – Pancreatic Cancer – Product Description 128

Table 278: University of Liverpool Pipeline Products & Ongoing Clinical Trials Overview 129

Table 279: Diagnostic Test – Pancreatic Cancer – Product Status 129

Table 280: Diagnostic Test – Pancreatic Cancer – Product Description 129

Table 281: Urine Test – Pancreatic Cancer – Product Status 130

Table 282: Urine Test – Pancreatic Cancer – Product Description 130

Table 283: University of Liverpool – Ongoing Clinical Trials Overview 131

Table 284: Diagnostic Test – Pancreatic Cancer – A Clinical Study of Diagnostic Test to Identify Pancreatic Cancer Earlier in Patients with New-onset Diabetes 132

Table 285: University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 133

Table 286: Biomarker Test – Pancreatic Cancer – Product Status 133

Table 287: Biomarker Test – Pancreatic Cancer – Product Description 133

Table 288: Liquid Biopsy Test – Pancreatic Cancer – Product Status 134

Table 289: Liquid Biopsy Test – Pancreatic Cancer – Product Description 134

Table 290: University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 135

Table 291: Biomarker Test – Pancreatic Cancer – Product Status 135

Table 292: Biomarker Test – Pancreatic Cancer – Product Description 135

Table 293: Protein Marker Test – Pancreatic Cancer – Product Status 136

Table 294: Protein Marker Test – Pancreatic Cancer – Product Description 136

Table 295: University of Washington Pipeline Products & Ongoing Clinical Trials Overview 137

Table 296: Diagnostic Test – Pancreatic Cancer – Product Status 137

Table 297: Diagnostic Test – Pancreatic Cancer – Product Description 137

Table 298: US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 138

Table 299: Blood-Based Biomarker – Pancreatic Cancer – Product Status 138

Table 300: Blood-Based Biomarker – Pancreatic Cancer – Product Description 138

Table 301: Vajra Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 139

Table 302: miRNA Biomarker – Pancreatic Cancer – Product Status 139

Table 303: miRNA Biomarker – Pancreatic Cancer – Product Description 139

Table 304: Vastcon Inc Pipeline Products & Ongoing Clinical Trials Overview 140

Table 305: Companion Diagnostic Assay – Pancreatic Cancer – Product Status 140

Table 306: Companion Diagnostic Assay – Pancreatic Cancer – Product Description 140

Table 307: Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 141

Table 308: PEGPH20 Companion Diagnostic Assay – Pancreatic Cancer – Product Status 141

Table 309: PEGPH20 Companion Diagnostic Assay – Pancreatic Cancer – Product Description 141

Table 310: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 142

Table 311: Viomics Diagnostic Assay – Pancreatic Cancer – Product Status 142

Table 312: Viomics Diagnostic Assay – Pancreatic Cancer – Product Description 142

Table 313: VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 143

Table 314: NuQ Diagnostic Test – Pancreatic Cancer – Product Status 143

Table 315: NuQ Diagnostic Test – Pancreatic Cancer – Product Description 143

Table 316: VolitionRX Ltd – Ongoing Clinical Trials Overview 144

Table 317: NuQ Diagnostic Test – Pancreatic Cancer – Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ Blood Test for Pancreatic Cancer 145

Table 318: ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 146

Table 319: Lipidomic Marker Test – Pancreatic Cancer – Product Status 146

Table 320: Lipidomic Marker Test – Pancreatic Cancer – Product Description 146

List of Figures

Figure 1: Pancreatic Cancer – Pipeline Products by Stage of Development 15

Figure 2: Pancreatic Cancer – Pipeline Products by Territory 16

Figure 3: Pancreatic Cancer – Pipeline Products by Regulatory Path 17

Figure 4: Pancreatic Cancer – Pipeline Products by Estimated Approval Date 18

Figure 5: Pancreatic Cancer – Ongoing Clinical Trials 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports